EP03: NGS in Transplant Immunology and Resolution of Genotyping
In this podcast episode, Professor Medhat Askar discusses the revolutionary changes in transplant immunology, focusing on his research and clinical practices related to organ and bone marrow transplantation.
Professor Askar delves into the significant advancements in genomic technologies that have transformed donor-recipient matching processes, thereby enhancing transplant success rates.
This episode also discusses the challenges in transplantation. The primary challenge is immune rejection, where the immune system recognizes and attacks the transplanted tissue. To combat this, significant emphasis is placed on matching donors and recipients through human leukocyte antigen (HLA) testing.
Professor Askar also talks about the technological advancements in genomic sequencing and the impact of next-generation sequencing.
Next-generation sequencing has been a game-changer by allowing high-resolution typing of genes, providing more accurate matching and predicting potential rejection scenarios. This technology became clinically viable about a decade ago and is increasingly accessible.
This podcast episode also discusses post-transplant monitoring. Professor Askar discusses the use of non-invasive techniques like donor-derived cell-free DNA, which offers a way to monitor organ rejection without the need for frequent biopsies.
The ability to sequence more donors at a lower cost has expanded the pool of potential matches, particularly important for bone marrow transplants. The episode concludes with Professor Askar expressing optimism about leveraging these technologies further to enhance transplant outcomes and patient care.
Tune in below to join the conversation!
MGI Podcast EP03：NGS in Transplant Immunology and Resolution of Genotyping
Medhat Askar is a senior executive physician with comprehensive experience across North America and the Gulf region, specializing in higher education administration, health professions education, and healthcare systems.
His expertise extends to quality management, accreditation, laboratory medicine, solid organ and hematopoietic cell transplantation, as well as cell and gene therapy.
Watch EP02 "Rare Disease Mendelian Disorders & Sequencing Breakthroughs" Now
About MGI
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. MGI focuses on R&D, production, and sales of DNA sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, mass spectrometry, medical imaging, and laboratory automation.
Founded in 2016, MGI has more than 2,900 employees, nearly half of whom are R&D personnel. MGI operates in 100 countries and regions and has established multiple research and production bases around the world. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.
